SCOTUS rebuffs Gilead, Merck appeals in high-profile battles by Arlene Weintraub Tuesday, January 8, 2019 Monday was a good-news-bad-news day for Gilead as the Supreme Court handed down two decisions about which appeals they'll consider.
DOJ moves to kill its Gilead false claims case by Eric Palmer Monday, December 3, 2018 The Justice Department will no longer pursue a whistleblower case against Gilead for using an unapproved API in some HIV drugs.
Express Scripts bars 48 drugs for 2019, hitting AbbVie, Gilead by Carly Helfand Tuesday, August 7, 2018 It’s that time of year again—the time when lead PBM Express Scripts ignites pharma’s ire with a brand-new list of formulary exclusions.
Gilead shelved safer HIV drugs to shield older drugs: lawsuit by Eric Sagonowsky Wednesday, May 9, 2018 Patients allege that Gilead held off on developing its better HIV candidates until older drugs neared the end of their patent lives.
Besieged Teva launches exclusive generic of Gilead's Viread by Eric Sagonowsky Friday, December 15, 2017 Amid tough times at the drugmaker, Teva is launching an exclusive generic to Gilead Sciences' hep B and HIV antiviral Viread.
FiercePharmaAsia—Gilead, Biocon and AstraZeneca by Angus Liu Friday, July 14, 2017 A whistleblower suit against Gilead is revived, Biocon and Mylan's Herceptin biosim is delayed, and AZ is upping production to meet demands in China.
Gilead faces new heat in HIV drug whistleblower suit by Eric Sagonowsky Monday, July 10, 2017 Gilead hit with revived lawsuit claiming it sourced a key HIV drug ingredient from an unapproved Chinese manufacturer.
8. Viread by Eric Sagonowsky Under a previous patent settlement with Gilead Sciences, Teva Pharmaceutical Industries will be able to launch a generic version of hepatitis B and HIV antiviral Viread late this year.
